Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 31Myelodysplastic Syndromes 26Multiple Myeloma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Lymphoma 18Hodgkin Disease 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Lymphoma, Non-Hodgkin 13Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Large B-Cell, Diffuse 10Hematologic Neoplasms 9Primary Myelofibrosis 8Leukemia, Myelomonocytic, Chronic 8Graft vs Host Disease 8Myeloproliferative Disorders 7Neoplasms, Plasma Cell 5Lymphoma, Follicular 5Leukemia, Myelomonocytic, Juvenile 5Recurrence 4Neoplasms 4Lymphoma, T-Cell 4Lymphoma, B-Cell, Marginal Zone 4Burkitt Lymphoma 4Breast Neoplasms 4Anemia, Aplastic 4Polycythemia Vera 3Lymphoma, Mantle-Cell 3Leukemia, Biphenotypic, Acute 3Hemoglobinuria, Paroxysmal 3

Interventions

Dexamethasone 6fludarabine 5Whole-Body Irradiation 5Mycophenolic Acid 5Melphalan 5Lenalidomide 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Tacrolimus 3Calcium Dobesilate 3Bortezomib 3dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2pomalidomide 1plerixafor 1pegylated granulocyte colony-stimulating factor 1liposomal doxorubicin 1ixazomib 1isatuximab 1ferric pyrophosphate 1elotuzumab 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Plasma Cell × Stem Cell Transplantation × Clear all
NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT00615589 2016-04-04

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

University of Michigan Rogel Cancer Center

Phase 2 Terminated
22 enrolled 9 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡